Skip to content

Precigen PGEN Debt-to-equity

Debt-to-equity at other companies

Bristol-Myers Squibb logo
Bristol-Myers SquibbBMY
2.2×-0.6×
Regeneron Pharmaceuticals logo
Regeneron PharmaceuticalsREGN
0.1×0.0×
Gilead Sciences logo
Gilead SciencesGILD
0.9×-0.4×
Viridian Therapeutics, Inc. logo
Viridian Therapeutics, Inc.VRDN
0.1×0.0×
Agios Pharmaceuticals logo
Agios PharmaceuticalsAGIO
0.0×
Arrowhead Research logo
Arrowhead ResearchARWR
0.2×0.0×

Other financials

Income statement

See full
Revenue$23.3M+1,634%
Operating income-$6.0M+73.5%
Net income-$7.9M+85.4%
EPS (diluted)-$0.02+88.9%

Balance sheet

See full
Cash & equivalents$7.5M+23.5%
Total debt$98.3M+1,714%
Total equity$20.2M+244%
Total assets$138.6M+7.6%

Cash flow

See full
Operating cash flow-$43.8M-168%
CapEx$258.0K-58.5%
Free cash flow-$44.1M-160%

Valuation

See full
Market cap$1.91B+213%
Enterprise value$2B+234%
P/S72×

Profitability

See full
Gross margin83.6%
Operating margin-2,890.9%
Net margin-3,656%
FCF margin-1,756.5%

Returns & leverage

See full
Return on equity-843.6%-1,103pp
Current ratio4.8×+1.3×

Where this comes from

Calculated from Precigen’s reported figures.

Based on the most recent quarter.

The official record: Precigen’s 10-Q, filed May 13, 2026, on SEC EDGAR. View the filing →

Ask your AI about Precigen's debt-to-equity.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI
Harbor at dusk
Claude

Questions, answered.

What is Precigen's debt-to-equity?
Precigen (PGEN) reported debt-to-equity of 4.9× in Q1 2026.
What is the long-term trend for Precigen's debt-to-equity?
Over 5 years (2020 to 2025), Precigen's debt-to-equity has grown at a 11.6% compound annual growth rate (CAGR), from 2.7× to 4.7×.
What does debt-to-equity mean?
Total debt (including capitalized leases and financing obligations) divided by shareholders' equity at the quarter end. Measures how much the company is financed by debt relative to equity.